Publikationen von M. Ising
Alle Typen
Zeitschriftenartikel (288)
281.
Zeitschriftenartikel
17 (1), S. 43 - 48 (2003)
Lithium augmentation increases post-dexamethasone cortisol in the dexamethasone suppression test in unipolar major depression. Depression and Anxiety 282.
Zeitschriftenartikel
45 (2), S. 236 - 240 (2003)
CFA as a method for genetic association studies in complex diseases. Psychology Science 283.
Zeitschriftenartikel
45 (2), S. 223 - 235 (2003)
Prediction of placebo responses by multiple regression methods and CFA. Re-analysis of an experiment conducted by W. Janke between 1963 and 1966. Psychology Science 284.
Zeitschriftenartikel
114 (7), S. 763 - 764 (2002)
Somatic complaints and somatosensory ERPs as vulnerability markers for affective disorders. American Journal of Medical Genetics 285.
Zeitschriftenartikel
114 (7), S. 766 - 767 (2002)
The combined dexamethasone-suppression/corticotropin-releasing-hormone(CRH) stimulation test, a possible endophenotype for major depression? American Journal of Medical Genetics 286.
Zeitschriftenartikel
16 (4), S. 241 - 242 (2002)
Auditory and somatosensory evoked potentials as vulnerability markers for affective disorders. Journal of Psychophysiology 287.
Zeitschriftenartikel
35, S. 83 - 94 (2001)
Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression: a prospective study. Journal of Psychiatric Research 288.
Zeitschriftenartikel
34, S. 171 - 181 (2000)
Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R 121919 in major depression: The first 20 patients treated. Journal of Psychiatric Research Buchkapitel (3)
289.
Buchkapitel
Moderne Depressionsbehandlung. In: Das Depressions-Buch für Pflege- und Gesundheitsberufe Menschen mit Depressionen gekonnt pflegen und behandeln, S. 49 - 73 (Hg. Hax-Schoppenhorst, T.; Jünger, S.). Hogrefe, Bern (2016)
290.
Buchkapitel
Stresshormonregulation und Depressionsrisiko - Perspektiven für die antidepressive Behandlung. In: Jahrbuch. Forschungsberichte und Publikationen 2011/12, 8 p. (Hg. der Wissenschaften, M.-P.-G. z. F.). Max-Planck-Gesellschaft zur Förderung der Wissenschaften, München (2012)
291.
Buchkapitel
Münchner Vulnerabilitätsstudie: Beitrag von "High-risk"-Studien zur Verlaufsforschung. In: Psychopathologie im Längsschnitt: Methoden, Analyse, Bewertung, S. 148 - 160 (Hg. Soyka, M.; Möller, H.-J.; Wittchen, H.-U.). ecomed, Landsberg/Lech (2003)
Konferenzbeitrag (4)
292.
Konferenzbeitrag
83 (9, Suppl.), S74, S. S375 - S376 (2018)
Perspective of Personalized Drug Treatment in Depression. 73rd Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry (SOBP), New York, NY, 10. Mai 2018 - 12. Mai 2018. BIOLOGICAL PSYCHIATRY 293.
Konferenzbeitrag
23 (3, Suppl.), P883, S. 457 - 457 (2017)
Cross-sectional study in German MS patients reveals unmet needs with regard to psychiatric comorbidity. 7th Joint
European Committee for Treatment and Research in Multiple Sclerosis
(ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, FRANCE, 25. Oktober 2017 - 28. Oktober 2017. MULTIPLE SCLEROSIS JOURNAL 294.
Konferenzbeitrag
27 (Suppl. 3), T24, S. S446 - S447 (2017)
SEX-SPECIFIC DNA METHYLATION SIGNATURES IN PANIC DISORDER. 24th World Congress of Psychiatric Genetics (WCPG), Jerusalem, ISRAEL, 30. Oktober 2016 - 04. November 2016. EUROPEAN NEUROPSYCHOPHARMACOLOGY 295.
Konferenzbeitrag
27 (Suppl. 2), Su48, S. S231 - S231 (2017)
EPIGENOME-WIDE ASSOCIATION STUDY (EWAS) IN A PANIC DISORDER COHORT. 23rd Annual World Congress of Psychiatric Genetics (WCPG), Toronto, CANADA, 16. Oktober 2015 - 20. Oktober 2015. EUROPEAN NEUROPSYCHOPHARMACOLOGY Meeting Abstract (11)
296.
Meeting Abstract
21 (10), S. 766 - 774. (2020)
Evidence for an enhanced procoagulant state in remitted major depression. In WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 297.
Meeting Abstract
29, S. S46 - S47. 31st Congress of the European-College-of-Neuropsychopharmacology (ECNP), Barcelona, SPAIN, 06. Oktober 2018 - 09. Oktober 2018. (2019)
Perspective of personalised drug treatment in depression. In EUROPEAN NEUROPSYCHOPHARMACOLOGY, 298.
Meeting Abstract
126 (11), S. 1522 - 1523. International Congress of the
World-Association-for-Stress-Related-and-Anxiety-Disorders (WASAD), Wurzburg, GERMANY, 03. Oktober 2019 - 05. Oktober 2019. (2019)
Interactions between FKBP5 variation and environmental stressors in adolescent major depression. In JOURNAL OF NEURAL TRANSMISSION, 299.
Meeting Abstract
66 (1), S. 119 - 119. (2019)
Evidence of a prothrombotic Condition in Patients with a remitted Depression. In ZEITSCHRIFT FUR PSYCHOSOMATISCHE MEDIZIN UND PSYCHOTHERAPIE, 300.
Meeting Abstract
88, S. 134 - 134. 25th World Congress of the
International-College-of-Psychosomatic-Medicine (ICPM) on Psychosomatic
Medicine, Florence, ITALY, 11. September 2019 - 13. September 2019. (2019)
Evidence for an enhanced procoagulant state in remitted major depression. In PSYCHOTHERAPY AND PSYCHOSOMATICS,